Subject: Survey to understand the practices of management in dysLIPIdemia with STATins and their combinations among healthcare practitioners in India (LIPISTAT)
Control of lipid levels is one of the most effective strategies for CVD prevention. Epidemiologic data have demonstrated the crucial role of dyslipidemia, especially hypercholesterolemia, in the development of CVD. Currently, statins are the first-line treatment in primary and secondary prevention of cardiovascular disease. They work by inhibiting the rate-limiting enzyme in cholesterol biosynthesis—3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase.
Statins are effective in primary and secondary prevention of cardiovascular diseases. They have a role in reducing LDL-C, but more importantly they have a strong evidence base, which shows a reduction in vascular event rates and all-cause mortality. In certain patient groups, however, statin monotherapy is not enough. There remains populations of patients who are either unable to tolerate statins or despite high-dose statin therapy continue to exhibit dyslipidemia and fail to meet recommended LDL-C levels. Given current unmet needs, there is a major requirement for additional therapeutic options for lipid lowering.
This multicenter survey is planned to get insights about management in dyslipidemia with statins and their combinations among healthcare practitioners in India.
We invite you to participate in this survey. On acceptance, you will need to fill the survey questionnaire form provided.
We would encourage you to carefully fill all available information to the fullest in the questionnaire.
If you agree to participate in the said survey, we would request you to sign and return the enclosed reply along with your visiting card for accuracy of records.
|
}}){kind=logo}
}})